Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 6, No 4 (2010) CLOPIDOGREL PHARMACOGENETICS Abstract  similar documents
A. N. Meshkov
"... of clopidogrel play an important role in the resistance development. Allel variants of the gene cytochrome CYP2C ..."
 
Vol 9, No 4 (2013) THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE Abstract  similar documents
K. B. Mirzaev, D. A. Sychev, D. A. Andreev, A. B. Prokofiev
"... The clinical significance  of CYP2C19 genetic polymorphism, associated with the violation ..."
 
Vol 14, No 5 (2018) Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case Abstract  similar documents
M. A. Andreyanova, K. B. Mirzaev, D. A. Sychev, K. A. Ryzhikova, A. V. Pokrovsky, A. F. Kharazov
"...   for resistance to antiplatelet therapy with clopidogrel. The decrease in the effectiveness of prolonged therapy ..."
 
Vol 6, No 2 (2010) THE MODERN ASPECTS OF CLOPIDOGREL USE Abstract  similar documents
E. N. Dankovtseva, D. A. Zateyshchikov
"... The possibilities and evidence base of clopidogrel use in clinical practice are discussed. Data ..."
 
Vol 11, No 1 (2015) EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE Abstract  similar documents
K. B. Mirzaev, D. A. Andreev, D. A. Sychev
"... of clopidogrel, the association of residual platelet reactivity with clinical outcomes and a review ..."
 
Vol 11, No 4 (2015) INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION Abstract  PDF (Eng)  similar documents
K. B. Mirzaev, R. E. Kazakov, V. V. Smirnov, D. A. Andreev, D. A. Sychev
"... .1 in the CYP2C19*1/*1 group vs 18.2±16.4 in the CYP2C19*1/*2 one (р=0.03). Clopidogrel laboratory resistance (P ..."
 
Vol 8, No 1 (2012) RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION Abstract  similar documents
V. A. Sulimov, E. V. Moroz
"... Aim. To study prevalence of resistance to acetylsalicylic acid, clopidogrel and dual resistance ..."
 
Vol 7, No 6 (2011) ANTI-INFLAMMATORY EFFECT OF CLOPIDOGREL IN ATHEROSCLEROSIS Abstract  similar documents
L. I. Buriachkovskaia, A. B. Sumarokov, I. A. Uchitel, E. M. Gupalo
"... Aim. To analyze the literary and own data about clopidogrel influence on platelets during ..."
 
Vol 6, No 4 (2010) ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY? Abstract  similar documents
S. J. Martsevich
"... The ACC/AHA clopidogrel clinical alert about the possibility of ineffective treatment ..."
 
Vol 7, No 1 (2011) THERAPEUTIC EQUIVALENCE OF ORIGINAL CLOPIDOGREL (PLAVIX) AND ITS GENERIC (EGITROMB). RESULTS OF COMPARATIVE RANDOMIZED CROSS-OVER BLIND STUDY Abstract  similar documents
V. V. Yakusevich, A. S. Petrochenko, V. A. Simonov, N. Yu. Levshin, A. D. Deev
"... Aim. To study therapeutic equivalence (efficacy, safety and tolerability) of original clopidogrel ..."
 
Vol 10, No 6 (2014) СONCOMITANT ADMINISTRATION OF CLOPIDOGREL AND PROTON PUMP INHIBITORS: ARE THERE ANY OPEN QUESTIONS LEFT TODAY? Abstract  similar documents
S. Yu. Martsevich, A. Yu. Suvorov
"... Concomitant administration of clopidogrel and proton pump inhibitors (PPI), the possible influence ..."
 
Vol 3, No 3 (2007) RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE Abstract  similar documents
D. H. Aynetdinova, A. E. Udovichenko, V. A. Sulimov
"... клопидогреля с АСК было показано снижение риска сосудистой смерти, ИМ и инсульта на 20% по сравнению с моно ..."
 
Vol 14, No 1 (2018) NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME Abstract  similar documents
K. B. Mirzaev, O. D. Konova, E. A. Grishina, K. A. Ryzhikova, Zh. A. Sozaeva, D. A. Andreev, M. Y. Gilyarov, D. A. Sychev
"... of carriership of at least one CYP4F2*3 allele on the risk of resistance to clopidogrel in patients with acute ..."
 
Vol 13, No 6 (2017) CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE Abstract  similar documents
A. I. Akhmetova, E. B. Kleimenova, D. A. Sychev, O. V. Parshina, L. P. Yashina
"... Aim. To study the use of CYP2C19 pharmacogenetic testing (PhGT) for personalization ..."
 
Vol 13, No 1 (2017) MONITORING OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE Abstract  similar documents
N. F. Puchinian, N. V. Furman, L. I. Malinova, P. V. Dolotovskaya
"... % 100 80 60 40 20 0 No CA / Без КАГ After CA / После КАГ ASA АСК Clopidogrel Клопидогрел ..."
 
Vol 7, No 1 (2011) THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS Abstract  similar documents
O. V. Gaisenok
"... in patients with cardioascular diseases are discussed. Role of clopidogrel in contemporary antiplatelet ..."
 
Vol 13, No 5 (2017) INFLUENCE OF SWITCHING OF CLOPIDOGREL TO TICAGRELOR ON THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ST SEGMENT ELEVATION Abstract  similar documents
E. V. Tavlueva, A. V. Alekseenko, O. V. Gruzdeva, O. L. Barbarash
"... Aim. To study the effect of replacing clopidogrel with ticagrelor on endpoints of hospital period ..."
 
Vol 5, No 5 (2009) EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME Abstract  similar documents
A. L. Alyavi, R. A. Rakhimov, B. A. Alyavi
"... and morphology of erythrocytes and to assess their changes during therapy with acetylsalicylic acid, emclopidogrel/em ..."
 
Vol 8, No 2 (2012) RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS Abstract  similar documents
A. A. Lomonosova, N. A. Mazur, E. A. Zolozova, E. V. Sayutina, V. V. Chigineva, N. V. Shestakova
"... Aim. To compare effects of acetylsalicylic acid (ASA) and two emclopidogrel/em drugs on residual ..."
 
Vol 7, No 3 (2011) MODERN ANTIPLATELET THERAPY OF ISCHEMIC HEART DISEASE PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS: DATA FROM EVIDENCE-BASED MEDICINE AND REAL PRACTICE Abstract  similar documents
S. Yu. Martsevich, M. L. Ginzburg, A. M. Malysheva, Yu. N. Polyanskaya, T. G. Kheliya, N. P. Kutishenko
"... Aim. To study a rate of emclopidogrel/em use in patients having indications for emclopidogrel/em therapy ..."
 
Vol 7, No 5 (2011) HIGH VERSUS STANDARD CLOPIDOGREL MAINTENANCE DOSE AFTER PERCUTANEOUS CORONARY INTERVENTION AND EFFECTS ON PLATELET INHIBITION, ENDOTHELIAL FUNCTION, AND INFLAMMATION. RESULTS OF THE ARMYDA-150 MG (ANTIPLATELET THERAPY FOR REDUCTION OF MYOCARDIAL DAMAGE DURING ANGIOPLASTY) RANDOMIZED STUDY  similar documents
G. Patti, D. Grieco, G. Dicuonzo, V. Pasceri, A. Nusca, G. Sciascio
"... Введение. Полученные ранее данные свидетельствуют о наличии у emклопидогрела/em не только ..."
 
Vol 2, No 3 (2006) ANTITHROMBOTIC THERAPY OF ISCHEMIC HEART DISEASE: FROM FAST ACTING ANTIAGGREGANTS TO STATINES AND NITRATE OXIDE. IS IT REAL? Abstract  similar documents
I. A. Latfullin, A. A. Podolskaya
"... , warfarin, ticlopidine and emclopidogrel/em are discussed. Study data on new antiplatelet drugs are given ..."
 
Vol 9, No 1 (2013) POSSIBILITIES OF CLINICAL LABORATORY EVALUATION OF ANTIPLATELET THERAPY EFFECTIVENESS IN PATIENTS WITH ISCHEMIC HEART DISEASE Abstract  similar documents
O. V. Sirotkina, A. B. Laskovets, A. S. Lipunova, L. B. Gaykovaya, S. A. Boldueva, T. V. Vavilova
"... and induced flow cytofluorometry during antiplatelet therapy with emclopidogrel/em and acetylsalicylic acid (ASA ..."
 
Vol 14, No 6 (2018) P2Y12 Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel Abstract  PDF (Eng)  similar documents
N. M. Vorobyeva
"... with emclopidogrel/em or ticagrelor was performed, as well as of all 3 P2Y12-receptor inhibitors among themselves ..."
 
Vol 12, No 4 (2016) High residual platelet reactivity during dual antiplatelet therapy, found by optical aggregometry and the rate of atherothrombotic complications after coronary artery stenting in patients with ischemic heart disease in clinical practice Abstract  similar documents
N. F. Puchinyan, N. V. Furman, P. V. Dolotovskaya, L. L. Malinova
"... antiplatelet therapy (DAT) with acetylsalicylic acid (ASA) and emclopidogrel/em by optical aggregometry in patients ..."
 
Vol 4, No 2 (2008) ANTIPLATELET THERAPY RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION Abstract  similar documents
D. H. Ainetdinova, A. Е. Udovichenko, V. A. Sulimov
"... Aim. To evaluate the incidence of acetylsalicylic acid (ASA) and emclopidogrel/em resistance ..."
 
Vol 14, No 2 (2018) NEPHROPROTECTIVE EFFECTS OF LISINOPRIL IN THE THERAPY OF HYPERTENSIVE PATIENTS WITH OBESITY Abstract  similar documents
S. G. Shulkina, Е. N. Smirnova
"... and improving the glomerular filtration rate (GFR) were found after 6 months. The emdecrease/em in serum cystatin C ..."
 
Vol 14, No 2 (2018) WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME Abstract  similar documents
M. Yu. Gilyarov, Е. V. Konstantinova
"... of reperfusion and the selected treatment strategy. Due to some limitations in the use of emclopidogrel/em ..."
 
Vol 5, No 3 (2009) ANTIPLATELET DRUGS RESISTANCE IN PATIENTS WITH ISCHEMIC HEART DISEASE AND OBLITERATIVE ATHEROSCLEROSIS OF LOWER LIMB ARTERIES ASSOCIATED WITH DIABETES MELLITUS TYPE 2 Abstract  similar documents
E. V. Gorjacheva, A. E. Udovichenko, V. A. Sulimov, N. V. Lavrishcheva, M. A. Surikova, T. N. Gracheva
"... Aim. To study a rate of resistance to acetylsalicylic acid (ASA) and emclopidogrel/em and clinical ..."
 
Vol 8, No 2 (2012) UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE Abstract  similar documents
S. Yu. Martsevich, V. P. Voronina, M. L. Ginzburg, N. P. Kutishenko, Yu. N. Polyanskaya, T. G. Kheliya, A. M. Malysheva, S. N. Tolpygina, V. S. Kutuzova, E. A. Gofman, A. D. Deev
"... Aim. To assess the real rate of dual antiplatelet therapy (DAT, acetylsalicylic acid + emclopidogrel/em ..."
 
Vol 2, No 4 (2006) ANGIOTENSIN CONVERTING ENZYME INHIBITORS: DECREASE IN HEART REMODELING AND IMPROVEMENT IN FUNCTION OF ENDOTHELIUM IN PATIENTS WITH ARTERIAL HYPERTENSION Abstract  similar documents
K. Yu. Nikolaev, G. I. Lifshits, A. A. Nikolaeva, I. M. Gicheva
"... реактивность, эналаприл РФК 2006; 4: 12-17 Angiotensin converting enzyme inhibitors: emdecrease/em in heart ..."
 
Vol 9, No 5 (2013) THE ASSESSMENT AND REDUCTION OF CARDIAC EVENTS RISK IN NONCARDIAC OPERATIONS: IS THERE A NEED FOR REVIEW OF RECOMMENDATIONS? Abstract  similar documents
A. N. Sumin
"... revascularization. The reason for this experts position has been a series of studies emDECREASE/em, performed ..."
 
Vol 3, No 2 (2007) VARFARIN DOSE REGIME APPROACHS BASED ON PHARMACOGENETICS TEST RESULTS: REAL POSSIBILITY TO OPTIMIZE THE PHARMACOTHERAPY Abstract  similar documents
D. A. Sychev, I. M. Antonov, S. V. Zagrebin, N. A. Gasanov, V. G. Kukes
"... of polymorphisms of genes of their biotransformation (emCYP/em2C9) and molecule-targets (VKORC1). This created basis ..."
 
Vol 13, No 4 (2017) GENETIC PREDICTORS OF INTENSIVE LIPID-LOWERING THERAPY EFFICACY AND ITS ANTI-INFLAMMATORY EFFECTS IN VERY HIGH CARDIOVASCULAR RISK PATIENTS Abstract  similar documents
M. A. Vorobyeva, M. M. Azova, O. O. Gigani, I. V. Garmash, S. V. Villevalde, Zh. D. Kobalava
"... , 62.1% of men) were included into the study. Polymorphism Phe189Ser of the emCYP/em3A4 (gene encoding ..."
 
Vol 14, No 1 (2018) COMPARATIVE ANALYSIS OF HOSPITAL PHARMACOTHERAPY OF CHRONIC HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTIONS IN 2009-2010 AND 2014-2015 Abstract  similar documents
O. V. Reshetko, A. V. Sokolov, E. V. Rykalina, N. V. Furman
"... receptors (AMCR), diuretics, oral anticoagulants, emclopidogrel/em increased (p0.05). In the structure ..."
 
Vol 9, No 6 (2013) THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY Abstract  similar documents
A. V. Shulkin, E. N. Yakusheva, N. M. Popova
"... ), encoding P-glycoprotein, in pharmacotherapy with digoxin, antiplatelet drugs (emclopidogrel/em tikagrelol ..."
 
Vol 1, No 2 (2005) INFLUENCE OF MENOPAUSE ON BLOOD PRESSURE DIPPING IN WOMEN WITH METABOLIC SYNDROME: A CASE-CONTROL STUDY Abstract  similar documents
D. A. Anichkov, N. A. Shostak
"... Aim. To study if menopause influences the blood pressure (BP) emdecrease/em level during nighttime ..."
 
Vol 11, No 4 (2015) EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME Abstract  similar documents
A. V. Rudakova, N. V. Lomakin
"... Dual antiplatelet therapy, including emclopidogrel/em and aspirin, in a significant share of patients ..."
 
Vol 12, No 5 (2016) Treatment Adherence as a New Choice Factor for Optimization of Oral Anticoagulation Therapy in Patients with Atrial Fibrillation and Hemostatic Gene Polymorphisms Abstract  PDF (Eng)  similar documents
Yu. P. Skirdenko, A. V. Shustov, V. V. Zherebilov, N. A. Nikolayev
"... Aim. To evaluate treatment adherence and prevalence of emCYP/em2C9 and VKORC1 gene mutations ..."
 
Vol 9, No 6 (2013) ANTIPLATELET THERAPY CONTROL: CREDIBILITY GAP OR SEARCH FOR NEW DECISIONS? Abstract  similar documents
Yu. I. Grinshtein, A. A. Kosinova, I. Yu. Grinshtein
"... антитромбоцитарного лечения и emснижение/em частоты сердечно-сосудистых катастроф. ..."
 
Vol 9, No 5 (2013) APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA Abstract  similar documents
D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev
"... аллельных ва- риантов emCYP/em2C9*2 и emCYP/em2C9*3 отмечается emснижение/em ак- тивности emCYP/em2C9, что приводит к emснижению/em ..."
 
Vol 4, No 4 (2008) CARDIOVASCULAR EVENT RISK REDUCTION WITH MEDICINES: DATA OF EVIDENCE BASED MEDICINE AND RECOMMENDATIONS TO PRACTITIONERS Abstract  similar documents
S. Y. Martsevich
"... 76 Рациональная Фармакотерапия в Кардиологии 2008;№4 emСнижение/em риска сердечно-сосудистых осложнений ..."
 
Vol 3, No 3 (2007) REDUCTION OF CUMULATIVE CARDIOVASCULAR RISK IN PATIENTS WITH ARTERIAL HYPERTENSION: THE ROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ACCORDING TO THE NEW EUROPEAN RECOMMENDATIONS Abstract  similar documents
M. N. Mamedov, N. A. Chepurina, Z. N. Tokareva, A. A. Evdokimova
"... studies. In high risk patients monotherapy with Enam (enalapril, Dr. Reddy’s) emdecreases/em blood pressure ..."
 
Vol 6, No 4 (2010) ACE INHIBITOR POSSIBILITIES IN CLINICAL PRACTICE: WHAT WE KNOW ABOUT THEM? Abstract  similar documents
D. V. Nebieridze, A. S. Safarian
"... периндо- прил. Ключевые слова: ингибиторы АПФ, вазопротекция, emснижение/em риска осложнений, рамиприл, генерик ..."
 
Vol 12, No 5 (2016) Clinical and Laboratory Predictors of Major Adverse Cardiac Events in Patients with Ischemic Heart Disease Following Elective Percutaneous Coronary Intervention Abstract  similar documents
E. Z. Golukhova, M. V. Grigoryan, M. N. Ryabinina, N. I. Bulaeva
"... antiplatelet therapy with acetyl salicylic acid and emclopidogrel/em. Numerous clinical characteristics ..."
 
Vol 7, No 4 (2011) VASCULAR BED PECULIAR PROPERTIES IN PATIENTS WITH ISCHEMIC HEART DISEASE AND ARTERIAL HYPERTENSION. ROLE OF ANTIPLATELET THERAPY Abstract  similar documents
L. A. Haisheva, S. V. Shlyk
"... of revealed disorders with antiplatelet agent — emclopidogrel/em 75 mg/day. Material and methods. 40 patients ..."
 
Vol 11, No 1 (2015) THE WAY OF ASSESSING THE ADHERENCE TO MODERN DRUG THERAPY CLINICAL GUIDELINES AIMED AT REDUCING THE RISK OF RECURRENT STROKE (ACCORDING TO THE LIS-2 REGISTER) Abstract  similar documents
A. Yu. Suvorov, S. Yu. Martsevich, N. P. Kutishenko, A. D. Deev, M. L. Ginzburg, A. V. Akimova, E. V. Daniels, N. A. Dmitrieva, L. Yu. Drozdova, N. Yu. Zhuravskaya, O. V. Lerman, Yu. V. Lukina, M. M. Loukianov, V. P. Smirnov, A. V. Fokina
"... ТЕРАПИИ, НАПРАВЛЕННОЙ НА emСНИЖЕНИЕ/em РИСКА ПОВТОРНОГО ИНСУЛЬТА (ПО ДАННЫМ РЕГИСТРА ЛИС-2) А.Ю. Суворов1*, С ..."
 
Vol 7, No 1 (2011) NEW ANTIPLATELET DRUGS (PART 1) Abstract  similar documents
A. B. Sumarokov
"... emклопидогрела/em emснижена/em. Наиболее частые генетические варианты полимор- физма emCYP/em 2В6, emCYP/em 2С9, emCYP/em2С19, emCYP/em 3A5 ..."
 
Vol 13, No 1 (2017) ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY Abstract  similar documents
E. А. Ushkalova, S. K. Zyryanov, E. V. Dumchenko
"... + emclopidogrel/em) can be prescribed to elderly patients with cardiovascular comorbidity who are deemed unsuitable ..."
 
Vol 13, No 3 (2017) ISCHEMIC HEART DISEASE AND RENAL DYSFUNCTION Abstract  similar documents
F. I. Belyalov
"... , are discussed. The analysis of the studies showed increasing difficulties in the diagnosis of IHD, and emdecrease/em ..."
 
Vol 10, No 5 (2014) DUAL ANTIPLATELET THERAPY IN THE REAL CLINICAL PRACTICE Abstract  similar documents
G. N. Guseva, T. V. Pavlova, I. L. Voronova, S. M. Chohlunov
"... .8% of patients also received combination of emclopidogrel/em and acetylsalicylic acid, but changed medicinal products ..."
 
Vol 11, No 5 (2015) Practical aspects of apixaban use in clinical practice: continuing the theme Abstract  similar documents
S. N. Bel'diev
"... Currently there are no generally accepted guidelines for the use of apixaban together with emCYP/em3A4 ..."
 
Vol 15, No 2 (2019) The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention Abstract  similar documents
A. S. Tereshchenko, E. V. Merkulov, A. N. Samko, S. A. Abugov
"... is emclopidogrel/em. It has been proven that the use of emclopidogrel/em to date not always reduces the risk of development ..."
 
Vol 9, No 6 (2013) COMPARATIVE EFFICACY OF CHRONIC HEART FAILURE TREATMENT WITH PERINDOPRIL OR CARVEDILOL IN PATIENTS WITH ALCOHOLIC OR IDIOPATHIC DILATED CARDIOMYOPATHY Abstract  similar documents
I. V. Zhirov, G. K. Sarbalinova, S. N. Tereschenko
"... алкоголем, хроническая сердечная недостаточность, карведилол, периндоприл, но- вая стратегия emснижения/em ..."
 
Vol 15, No 2 (2019) Correction of Hypertriglyceridemia as the Way to Reduce Residual Risk in Diseases Caused by Atherosclerosis. Conclusion of the Advisory Board of the Russian Society of Cardiology, the Russian Scientific Medical Society of Therapists, the Eurasian Association of Therapists, the Russian National Atherosclerosis Society, the Russian Association of Endocrinologists, and the National League of Cardiologic Genetics Abstract  similar documents
G. P. Arutyunov, S. A. Boytsov, M. I. Voyevoda, V. S. Gurevich, O. M. Drapkina, V. V. Kukharchuk, A. I. Martynov, I. V. Sergiyenko, M. V. Shestakova, A. S. Aliyeva, N. M. Akhmedzhanov, M. G. Bubnova, А. S. Galyavich, I. G. Gordeyev, M. V. Ezhov, Yu. A. Karpov, V. O. Konstantinov, S. V. Nedogoda, E. M. Nifontov, Ya. A. Orlova, A. V. Panov, S. A. Sayganov, V. V. Skibitskiy, E. I. Tarlovskaya, S. A. Urazgildeyeva, Yu. Sh. Khalimov
"... the triglycerides concentration is their level more than 2.3 mmol/l. Statins are drugs of choice aimed to emdecrease/em ..."
 
Vol 12, No 5 (2016) Features of the Hemostasis and Platelets Enzyme Activity in Patients with Different Sensitivity to Acetylsalicylic Acid by the Acute Coronary Syndrome Abstract  similar documents
I. Yu. Grinshtein, A. A. Savchenko, Yu. I. Grinshtein, M. M. Petrova
"... with ASA and emclopidogrel/em, risk of thrombotic events is saved in ASA resistant patients with ACS ..."
 
Vol 8, No 4 (2012) ALTERNATIVE APPROACHES TO THE USE OF TWO COMPONENT ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME: EVIDENCES, RECOMMENDATIONS AND REAL PRACTICE Abstract  similar documents
S. R. Gilyarevskiy, V. A. Orlov, I. M. Kuz'mina, A. G. Larin
"... - фективности применения тикагрелора по сравнению с emклопидогрелом/em свидетельствовало и emснижение/em общей смертности ..."
 
Vol 14, No 4 (2018) Role of Single Nucleotide Polymorphism of СУР17А Gene in the Development of Stroke Abstract  similar documents
S. Yu. Nikulina, V. A. Shulman, A. A. Chernova, D. A. Nikulin, A. A. Semenchukov, O. V. Marilovceva, S. S. Tret'jakova, I. I. Lebedeva, V. N. Maksimov
"...  emCYP/em17A1 is one of the many genes that can participate in the formation of predisposition ..."
 
Vol 7, No 6 (2011) CORONARY EMBOLISM WITH FRAGMENTED THROMBUS FROM THE LEFT VENTRICLE IN PATIENT WITH POSTINFARCTION ANEURYSM Abstract  similar documents
Yu. F. Salakhova, S. V. Gar'kina, T. V. Kislukhin, D. V. Duplyakov, V. S. Ivanov, E. R. Perunova, E. I. Bazhenova, S. E. Burnazyan, S. M. Khokhlunov
"... therapy (acetylsalicylic acid, emclopidogrel/em, warfarin) was made on the 4th day of disease onset taking ..."
 
Vol 14, No 3 (2018) APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN Abstract  similar documents
O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova
"... in trials and proven efficacy in the prevention of stroke/systemic embolism, the use of emclopidogrel/em ..."
 
Vol 11, No 2 (2015) THE EFFECTIVENESS OF LERCANIDIPINE IN REDUCING THE RISK OF ARTERIAL HYPERTENSION COMPLICATIONS Abstract  similar documents
E. EL. Trisvetova
"... Несмотря на прогресс в emснижении/em риска развития осложнений артериальной гипертензии (АГ), контроль ..."
 
Vol 1, No 2 (2005) SYSTOLIC BLOOD PRESSURE REDUCTION: DO ALL THE DRUGS HAVE THE SAME EFFICIENCY? Abstract  similar documents
S. V. Nedogoda
"... диуретики на сегодняшний день являются наиболее перспективными препаратами для emснижения/em систолического АД ..."
 
Vol 7, No 3 (2011) REDUCTION DEGREE OF LOW-DENSITY LIPOPROTEINS CHOLESTEROL LEVELS ACCORDING TO DIFFERENT DOSES OF STATINS; ITS EFFECT ON THE RISK OF ISCHEMIC HEART DISEASE ACUTE EPISODES DEPENDING ON TREATMENT DURATION; AND RISK OF ISCHEMIC AND THROMBOEMBOLIC STROKE. COMMENT ON THE PAPER OF LAW M.R., WALD N.J., RUDNICKA A.R. QUANTIFYING EFFECT OF STATINS ON LOW DENSITY LIPOPROTEIN CHOLESTEROL, ISCHAEMIC HEART DISEASE, AND STROKE: SYSTEMATIC REVIEW AND META-ANALYSIS. BMJ 2003; 326:1423-1427 Abstract  similar documents
N. V. Perova
"... emdecrease/em in LDL cholesterol levels on 1.0 or 1.8 mmol/l leads to rate reduction in ischemic heart disease ..."
 
Vol 11, No 2 (2015) CLINICAL CASE HISTORY OF EPTIFIBATIDE USE DURING CORONARY INTERVENTION IN PATIENT WITH CORONARY FAILURE Abstract  similar documents
K. A. Kireev, A. V. Krasnopeev, T. S. Kireeva
"... antiplatelet drugs (acetylsalicylic acid and emclopidogrel/em) and heparin. There were not any reasons ..."
 
Vol 8, No 2 (2012): РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ ОСТРОГО КОРОНАРНОГО СИНДРОМА БЕЗ СТОЙКОГО ПОДЪЕМА СЕГМЕНТА ST Abstract  similar documents
, , , , , , , , , , , , , , , ,
"... , бивалирудин, шунтирование, отделение неотложной кардиологии, emклопидогрел/em, диабет, эноксапарин, Европейское ..."
 
Vol 11, No 5 (2015) Subscription to the journal Abstract  similar documents
article Editorial
"... ) ISSN 1819-6446 (Print) ISSN 2225-3653 (Online) emCYP/em3A4 and emCYP/em2C19: emclopidogrel/em antiplatelet effect in ..."
 
Vol 15, No 3 (2019) Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population Abstract  similar documents
K. B. Mirzaev, D. S. Fedorinov, D. V. Ivashchenko, D. A. Sychev
"... ", "cardiology" together with the terms associated with the polymorphic marker, including: «P450», «emCYP/em2C19 ..."
 
Vol 10, No 6 (2014) PHARMACOGENETIC TESTING OPPORTUNITIES IN CARDIOLOGY BASED ON EXOME SEQUENCING Abstract  similar documents
N. V. Shcherbakova, A. I. Ershova, A. A. Suvorova, E. Y. Hlebus, A. N. Meshkov, S. A. Boytsov
"... . emКлопидогрел/em, emCYP/em2C19 Кровотечение или уменьшение Рассмотреть возможность назначения Тикагрелор, эффективности ..."
 
Vol 13, No 3 (2017) PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION Abstract  similar documents
A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko
"... on the pharmacokinetics of these drugs. RE-LY study showed a 15% emdecrease/em in trough dabigatran concentration and 27% lower ..."
 
Vol 14, No 1 (2018) NEW APPROACHES TO INDIVIDUALIZED CHOICE OF ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION Abstract  similar documents
Ju. P. Skirdenko, N. A. Nikolayev
"... , polymorphism of genes emCYP/em2C9 and VKORC1 and the structure of food preferences. Results. Persons ..."
 
Vol 11, No 2 (2015) PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST Abstract  similar documents
D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii
"... laboratory control and monitoring are needed, drugs interactions (at the level of emCYP/em3A4, P-gp), management ..."
 
Vol 9, No 3 (2013) ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT Abstract  similar documents
E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts
"... - ется emснижение/em активности emCYP/em2C9, что приводит к emснижению/em клиренса непрямых антикоагулянтов. Это имеет ..."
 
Vol 5, No 4 (2009) GASTROENTEROPATHIES ASSOCIATED WITH ACETYLSALICYLIC ACID: HOW TO IMPROVE SAFETY OF THERAPY Abstract  similar documents
A. L. Komarov
"... in patients with atherothrombosis. Up to date the mostly comprehensible way to emdecrease/em gastrointestinal ..."
 
Vol 7, No 5 (2011) NEW ANTIPLATELET DRUGS. PART 2 Abstract  similar documents
A. B. Sumarokov
"... повышенных её значениях — относительно неудобное свойство emклопидогрела/em. В настоящее время для более быстрого ..."
 
Vol 15, No 3 (2019) Hypertension and Headache: the Effect of Antihypertensive Drugs Abstract  similar documents
V. A. Parfenov, T. M. Ostroumova, O. D. Ostroumova
"... . There was a statistically significant emdecrease/em in the frequency of headaches compared to placebo during treatment with beta ..."
 
Vol 12, No 1 (2016) Acute coronary syndrome and renal dysfunction Abstract  similar documents
F. I. Belyalov
"... У пациентов с острым коронарным синдромом коморбидное emснижение/em функции почек затрудняет ..."
 
Vol 9, No 2 (2013) EFFECT OF CHOLESTEROL BLOOD LEVEL REDUCTION BEGINNING EARLY IN LIFE ON THE RISK OF ISCHEMIC HEART DISEASE Abstract  similar documents
N. V. Perova
"... Комментарий к статье B.A. Ference et al. Влияние длительного emснижения/em холестерина липопротеинов ..."
 
Vol 1, No 1 (2005) TOBACCO DEPENDENCE TREATMENT WITH NICOTINE REPLACEMENT THERAPY AS ONE OF THE METHODS FOR CARDIOVASCULAR DISEASE RISK REDUCTION Abstract  similar documents
O. V. Vikhireva, S. A. Shalnova, A. D. Deev
"... удовлетворительной безопасностью и хорошо переносился. Прогнозируемое emснижение/em ожидаемого ОР смерти от ССЗ составило ..."
 
Vol 6, No 6 (2010) REDUCTION OF CARDIOVASCULAR COMPLICATIONS OF MODERN HYPOGLYCEMIC THERAPY OF DIABETES MELLITUS TYPE 2: "FLORENTINE HERESY" Abstract  similar documents
A. A. Aleksandrov
"... emснижение/em степени гипергликемии [2], и контроль уровня глюко- зы в крови доминирует в сознании и практике ..."
 
Vol 4, No 5 (2008) CRESTOR SHOWN SIGNIFICANT REDUCTION OF CARDIOVASCULAR RISK IN A LARGE CLINICAL TRIAL Abstract  similar documents
статья Редакционная
"... ПРОДЕМОНСТРИРОВАЛ ЗНАЧИТЕЛЬНОЕ emСНИЖЕНИЕ/em СЕРДЕЧНО-СОСУДИСТОГО РИСКА В КРУПНОМ КЛИНИЧЕСКОМИССЛЕДОВАНИИ ..."
 
Vol 9, No 6 (2013) THROMBOLYSIS OR PRIMARY PCI FOR MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION? THE STREAM TRIAL (STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION) Abstract  similar documents
V. A. Sulimov
"... by half in patients aged ≥75 years) in combination with emclopidogrel/em and enoxaparin followed by admission ..."
 
Vol 9, No 1 (2013) OUTPATIENT REGISTER OF CARDIOVASCULAR DISEASES IN THE RYAZAN REGION (RECVASA): PRINCIPAL TASKS, EXPERIENCE OF DEVELOPMENT AND FIRST RESULTS Abstract  PDF (Eng)  similar documents
S. A. Boytsov, S. S. Yakushin, S. Yu. Martsevich, M. M. Lukyanov, N. N. Nikulina, A. V. Zagrebelny, A. N. Vorobyov, K. G. Pereverseva, E. A. Pravkina, A. D. Deev, E. Yu. Andreenko, A. I. Ershova, A. N. Meshkov, R. P. Myasnikov, S. E. Serdyuk, М. S. Kharlap
"... : antiplatelet agents – in 60.4% of the cases (584 patients received acetylsalicylic acid and 20 – emclopidogrel/em ..."
 
Vol 5, No 5 (2009) ANTIAGGREGANT THERAPY OVERCOMES LIMITS Abstract  similar documents
I. Andreeva
"... выписки из стационара (или не бо- лее 4 недель). В группе emклопидогрела/em наблюдали до- стоверное emснижение/em ..."
 
Vol 6, No 4 (2010) ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION: PROBLEMS AND PROSPECTS Abstract  similar documents
A. Y. Rychkov, N. Y. Khor'kova, A. A. Bliznyakov
"... убедительные данные клинических исследований о возможности эффективного emснижения/em частоты тромбоэмболических ..."
 
Vol 9, No 1 (2013) EFFECT OF LONG-TERM EXPOSURE TO LOWER LOW-DENSILIPOPROTEIN CHOLESTEROL BEGINNING EARLY IN LIFE ON THE RISK OF CORONARY HEART DISEASE. A MENDELIAN RANDOMIZATION ANALYSIS Abstract  similar documents
B. A. Ference, W. Yoo, I. Alesh, N. Mahajan, K. K. Mirowska, A. Mewada, J. Kahn, L. Afonso, K. A. Williams, J. M. Flack
"... Цель. Оценить эффект долгосрочного emснижения/em плазменной концентрации холестерина липопротеинов ..."
 
Vol 7, No 6 (2011) PHARMACOTHERAPY ANALYSIS OF ACUTE ST-ELEVATION MYOCARDIAL INFARCTION IN HOSPITALS OF VARIOUS TYPES Abstract  similar documents
R. M. Magdeev, O. V. Reshetko, E. Y. Rudnichenko, N. V. Furman, P. V. Dolotovskaya, T. Y. Grozdova, L. N. Volkova
"... , and emclopidogrel/em was not prescribed. At the same hospital clotting time was determined for monitoring of heparin ..."
 
Vol 9, No 6 (2013) DYNAMICS IN MEDICAL TREATMENT OF ISCHEMIC HEART DISEASE IN CLINICAL PRACTICE Abstract  PDF (Eng)  similar documents
S. A. Shalnova, A. D. Deev, S. A. Boytsov
"... молекулярной генетики того же центра emDecrease/em in cardiovascular mortality rate in ma- jority of developed ..."
 
Vol 4, No 2 (2008) COMPARATIVE STUDY OF EFFICIENCY AND SAFETY OF THE NEW DRUG OF AMLODOPINE – S-AMLODOPINE IN PATIENTS WITH ARTERIAL HYPERTENSION OF I-II DEGREE Abstract  similar documents
M. A. Maksimova, Y. V. Lukina, S. N. Tolpygina, E. V. Shilova, N. A. Dmitrieva, S. Y. Martsevich
"... drugs showed antihypertensive effect: significant emdecrease/em in average levels of systolic and diastolic ..."
 
Vol 10, No 4 (2014) STATINS AND PERCUTANEOUS CORONARY INTERVENTION. FOCUS ON THE ATORVASTATIN Abstract  similar documents
N. G. Gogolashvili
"... Обсуждаются возможности аторвастатина в emснижении/em риска развития перипроцедурного инфаркта миокарда ..."
 
Vol 8, No 1 (2012) THE EFFICACY OF HIGH-DOSE SIMVASTATIN IN ACUTE PERIOD OF ISCHEMIC STROKE Abstract  similar documents
V. V. Yakusevich, A. Yu. Malygin, S. V. Lychenko, A. S. Petrochenko, A. V. Kabanov
"... receiving simvastatin. The same patients revealed more intense and quick emdecrease/em in desquamated plasma ..."
 
Vol 1, No 2 (2005) ASSESSMENT OF RILMENIDINE EFFICIENCY IN PATIENTS WITH ARTERIAL HYPERTENSION WITH DETERIORATION OF DAILY PROFILE OF BLOOD PRESSURE Abstract  similar documents
P. P. Tikhonov, L. A. Sokolova
"... : with adequate emdecrease/em of BP at nighttime (dipper, D), and with insufficient emdecrease/em of BP at nighttime (non ..."
 
Vol 13, No 1 (2017) RESULTS OF HOSPITAL USE OF RECOMBINANT NON-IMMUNOGENIC STAPHYLOKINASE IN PATIENTS WITH ST-ELEVATED MYOCARDIAL INFARCTION Abstract  similar documents
V. B. Kostogryz
"... electrocardiogram after 90 minutes from the first bolus of recombinant non-immunogenic staphylokinase, the emdecrease/em ..."
 
Vol 3, No 3 (2007) MAXIMAL REDUCTION OF CARDIOVASCULAR COMPLICATIONS RISK – THE MAIN TASK OF MODERN THERAPY FOR HIGH RISK PATIENTS. RANDOMIZED STUDY ON COMPREHENSIVE CONTROL ON ARTERIAL HYPERTENSION AND DYSLIPIDAEMIA Abstract  similar documents
N. P. Kutishenko, V. V. Yakusevich, A. A. Seragzim, A. D. Deev, S. Y. Martsevich
"... Максимальное emснижение/em риска сердечно-сосудистых осложнений – главная цель современной терапии ..."
 
Vol 15, No 2 (2019) A Flexible Regimen of Combination Antihypertensive Therapy for Lower Blood Pressure to the Lower Target Level. Viewpoint of Cardiologist and Clinical Pharmacologist Abstract  similar documents
S. R. Gilyarevskiy, M. V. Golshmid, G. Yu. Zaharova, I. M. Kuzmina, I. I. Sinitsina
"... артериальной гипертонией, у которых для улучшения прогноза может быть полезно emснижение/em артериального давления ..."
 
Vol 7, No 4 (2011) PROTHROMBOTIC POLYMORPHISMS AND LONG-TERM PROGNOSIS OF PATIENTS WITH STABLE ISCHEMIC HEART DISEASE Abstract  similar documents
A. L. Komarov, O. O. Shahmatova, D. V. Rebrikov, D. Yu. Trophimov, T. I. Kotkina, T. A. Ilyushenko, A. D. Deev, E. P. Panchenko
"... variants as MTHFR C667 T/СТ and 1298 AА impacted prognosis only given concomitant emdecrease/em in plasma folate ..."
 
Vol 13, No 4 (2017) HIGH DOSES OF STATINS BEFORE PERCUTANEOUS CORONARY INTERVENTION: WHETHER THERE ARE REASONS TO USE? Abstract  similar documents
I. S. Yavelov, M. V. Zhatkina, O. M. Drapkina, A. Yu. Gorshkov, N. O. Myasnikova
"... to reduce myocardial damage with a emdecrease/em in the risk of periprocedural myocardial infarction. This effect ..."
 
Vol 13, No 4 (2017) TAKOTSUBO SYNDROME AS ACUTE FORM OF MICROVASCULAR ANGINA. CLINICAL CASE Abstract  similar documents
S. A. Boldueva, M. V. Ryzhikova, N. S. Shvets, I. A. Leonova, I. Yu. Titova, I. N. Kochanov
"... abnormalities were revealed: emdecrease/em in global contractility of the myocardium, hyperkinesia of the basal parts ..."
 
Vol 14, No 2 (2018) DOCTOR’S ADHERENCE TO RECOMMENDATIONS GOVERNING THE ANTIPLATELET AGENTS USE IN THE CARDIOVASCULAR DISEASES PREVENTION AND TREATMENT Abstract  similar documents
N. В. Perepech, A. V. Tregubov
"... . 51.8% of respondents recommend a combination of acetylsalicylic acid and emclopidogrel/em ..."
 
Vol 14, No 6 (2018) Availability and Affordability of Medicines for the Treatment of Cardiovascular Diseases in Pharmacies in Six Regions of the Russian Federation Abstract  PDF (Eng)  similar documents
A. E. Imaeva, Yu. A. Balanova, A. V. Kontsevaya, A. V. Kapustina, D. V. Duplyakov, O. H. Malysheva, I. V. Osipova, T. A. Petrichko, G. I. Kropanin, R. A. Kasimov, D. A. Leon, M. McKee
"... pharmacies. Among antiplatelet agents, aspirin was available in most pharmacies, and emclopidogrel/em was mostly ..."
 
Vol 14, No 6 (2018) Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice Abstract  PDF (Eng)  similar documents
K. G. Pereverzeva, S. S. Yakushin, A. E. Pripadcheva, N. P. Agaltsova
"... (3.8%) patients. Aspirin was the only antiplatelet agent in 3 cases and emclopidogrel/em – in one case ..."
 
1 - 100 of 1195 Items 1 2 3 4 5 6 7 8 9 10 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)